Berdagang Vir Biotechnology VIR

VirBiotechnology carta live

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tunjukkan lebih lagi
Noah Lee 2025 Sep 05, 14:20

US Job Growth Slows, Unemployment Rises: Rate Cut Outlook Intensifies

Emma Rose 2025 Sep 05, 14:20

Global Market Overview: Weak Nonfarm Data, Gold Hits Highs, OPEC+ Considers Output Hike

Emma Rose 2025 Sep 05, 13:20

US Job Growth Slows, Unemployment Rises: Fed Rate Cut Expectations Surge

Sophia Claire 2025 Sep 05, 12:20

Tesla Proposes a Potential $1 Trillion Compensation Plan for Elon Musk

Emma Rose 2025 Sep 05, 12:20

August Non-Farm Payroll Report: Will it Trigger a Fed Rate Cut?

Sophia Claire 2025 Sep 05, 11:20

US Non-Farm Payrolls August: Impact on Fed Rate Decision

Emma Rose 2025 Sep 05, 10:20

US Job Growth Slowdown: Fed Rate Cut Outlook Intensifies

Liam James 2025 Sep 05, 08:20

Gold Soars to Record Highs: Analysis and Future Outlook

Maklumat

Sebaran nilai

0.05

Spread (%)

0.9506 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Isnin

13:31 - 19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Khamis

13:31-19:59

Jumaat

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

765427200

Saham Tertunggak

138916000

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-4.01

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tunjukkan lebih lagi
Trustpilot